CN100435785C - 抑制iapp的化合物或其可药用酯或其可药用盐的制药应用 - Google Patents
抑制iapp的化合物或其可药用酯或其可药用盐的制药应用 Download PDFInfo
- Publication number
- CN100435785C CN100435785C CNB008107203A CN00810720A CN100435785C CN 100435785 C CN100435785 C CN 100435785C CN B008107203 A CNB008107203 A CN B008107203A CN 00810720 A CN00810720 A CN 00810720A CN 100435785 C CN100435785 C CN 100435785C
- Authority
- CN
- China
- Prior art keywords
- tetrahydroisoquinoline
- iapp
- group
- tetrahydro isoquinolyl
- sulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
化合物 | 活性 |
3-(3-羟基-1-丙基)氨基-1-丙磺酸 | 有活性 |
DL-2-氨基-5-磷酸戊酸 | 有活性 |
1,2,3,4-四氢异喹啉盐酸盐 | 有活性 |
环己基氨基磺酸钠盐 | 有活性 |
O-磷酸-L-丝氨酸 | 有活性 |
六氟戊二酸 | 有活性 |
8-甲氧基-5-喹啉磺酸钠盐 | 有活性 |
4-苯基-1-(3’-磺基丙基)-1,2,3,6-四氢吡啶钠盐 | 有活性 |
3-氨基-2-羟基-1-丙磺酸 | 有活性 |
3-二甲基氨基-1-丙磺酸 | 有活性 |
Claims (8)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13554599P | 1999-05-24 | 1999-05-24 | |
US60/135,545 | 1999-05-24 | ||
US14312399P | 1999-07-09 | 1999-07-09 | |
US60/143,123 | 1999-07-09 | ||
US09/576,677 | 2000-05-23 | ||
US09/576,677 US6562836B1 (en) | 1999-05-24 | 2000-05-23 | Methods and compounds for inhibiting amyloid deposits |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008101498521A Division CN101396352A (zh) | 1999-05-24 | 2000-05-24 | 抑制淀粉样蛋白沉积的方法和化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1377260A CN1377260A (zh) | 2002-10-30 |
CN100435785C true CN100435785C (zh) | 2008-11-26 |
Family
ID=27384726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008107203A Expired - Fee Related CN100435785C (zh) | 1999-05-24 | 2000-05-24 | 抑制iapp的化合物或其可药用酯或其可药用盐的制药应用 |
Country Status (13)
Country | Link |
---|---|
US (3) | US6562836B1 (zh) |
EP (1) | EP1227803B1 (zh) |
JP (1) | JP2003500350A (zh) |
CN (1) | CN100435785C (zh) |
AT (1) | ATE466571T1 (zh) |
AU (1) | AU4905000A (zh) |
CA (2) | CA2684016A1 (zh) |
DE (1) | DE60044365D1 (zh) |
HK (1) | HK1050133A1 (zh) |
IL (3) | IL146681A0 (zh) |
MX (1) | MXPA01011989A (zh) |
NZ (3) | NZ541238A (zh) |
WO (1) | WO2000071101A2 (zh) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
AU4282400A (en) * | 1999-04-28 | 2000-11-10 | Neurochem (International) Limited | Compositions and methods for treating amyloidosis |
US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
AU5994900A (en) * | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
WO2003029169A2 (en) | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
KR100948278B1 (ko) * | 2002-02-07 | 2010-03-18 | 히토시 엔도 | 방향족 아미노산 유도체 및 의약 조성물 |
WO2004058686A1 (en) | 2002-04-30 | 2004-07-15 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer’s disease |
PT1511710E (pt) * | 2002-05-31 | 2014-02-26 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
US20040167183A1 (en) * | 2003-02-20 | 2004-08-26 | The Procter & Gamble Company | Phenethylamino sulfamic acids |
CA2521189A1 (en) * | 2003-04-11 | 2004-10-28 | Gabor Tigyi | Lysophosphatidic acid analogs and inhibition of neointima formation |
US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
US7253306B2 (en) * | 2003-06-23 | 2007-08-07 | Neurochem (International) Limited | Pharmaceutical drug candidates and methods for preparation thereof |
US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
AU2011250847B2 (en) * | 2003-06-23 | 2013-06-20 | Bhi Limited Partnership | Methods and compositions for treating amyloid-related diseases |
AU2004249527A1 (en) * | 2003-06-23 | 2004-12-29 | Bellus Health (International) Limited | Methods and compositions for treating amyloid-related diseases |
CN100528840C (zh) * | 2003-06-23 | 2009-08-19 | 贝卢斯健康(国际)有限公司 | 改进的候选药物及其制备方法 |
SI1646659T1 (sl) * | 2003-06-23 | 2014-07-31 | Kiacta Sarl | Postopek za pripravo spojin 1,3-propan disulfonske kisline |
US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
WO2005079830A1 (en) * | 2004-02-23 | 2005-09-01 | Paul Fraser | Inhibitors of amyloid fibril formation and uses thereof |
ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
BRPI0517790A (pt) * | 2004-11-12 | 2008-10-21 | Neurochem Int Ltd | métodos e composições fluoradas para tratar doenças relacionadas à amilóide |
EP1817305A2 (en) * | 2004-11-16 | 2007-08-15 | Neurochem (International) Limited | Compounds for the treatment of cns and amyloid associated diseases |
EP1836161B1 (en) * | 2004-12-22 | 2016-07-20 | BHI Limited Partnership | Methods and compositions for treating amyloid-related diseases |
EP1874285B1 (en) * | 2005-04-07 | 2009-10-07 | Astrum Therapeutics Pty, Ltd. | Complementary compositions to reduce blood glucose levels and treat diabetes |
WO2006110477A2 (en) * | 2005-04-07 | 2006-10-19 | Astrum Therapeutics Pty. Ltd. | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus |
TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
WO2006125324A1 (en) * | 2005-05-27 | 2006-11-30 | Queen's University At Kingston | Treatment of protein folding disorders |
US20070049638A1 (en) * | 2005-07-21 | 2007-03-01 | Neurochem (International) Limited | Polymorphic forms of 3-amino-1-propanesulfonic acid |
EP1968561B8 (en) * | 2005-12-22 | 2010-10-20 | Kiacta Sàrl | Treatment of diabetic nephropathy |
PT3851447T (pt) | 2006-10-12 | 2023-12-11 | Bellus Health Inc | Métodos, compostos, composições e veículos para administrar ácido 3-amino-1-propanossulfónico |
CA2671904C (en) * | 2006-12-06 | 2012-07-03 | Cornell Research Foundation, Inc. | Intermediate duration neuromuscular blocking agents and antagonists thereof |
AU2007337806A1 (en) * | 2006-12-22 | 2008-07-03 | Bellus Health (International) Limited | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
KR101755178B1 (ko) * | 2008-11-14 | 2017-07-06 | 비에이치아이 리미티드 파트너쉽 | 유기 영양 염, 제조 방법 및 용도 |
US8592451B2 (en) | 2009-03-17 | 2013-11-26 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
CA2760837C (en) * | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
IN2012DN00352A (zh) * | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
EP2464626A4 (en) | 2009-08-10 | 2015-12-16 | Bhi Ltd Partnership | PROCESSES, COMPOUNDS AND COMPOSITIONS FOR THE EXPORTS OF 1,3-PROPANE-SULFONIC ACID |
CN102573794B (zh) | 2009-08-19 | 2017-03-15 | 康奈尔大学 | 供生理注射用的半胱氨酸 |
US20130143804A1 (en) * | 2010-06-07 | 2013-06-06 | Trustees Of The University Of Pennsylvania | Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus |
MX357628B (es) | 2010-08-16 | 2018-07-17 | Cognoptix Inc Star | Sistema y metodo para detectar proteinas amiloides. |
EP2714682B1 (en) | 2011-05-24 | 2016-03-16 | Università degli Studi di Bari "Aldo Moro" | Novel tetrahydroisoquinoline compounds for use in the diagnosis and treatment of neurodegenerative diseases |
US9353063B2 (en) | 2011-11-30 | 2016-05-31 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
SI3052096T1 (en) | 2013-10-03 | 2018-04-30 | Kura Oncology, Inc. | EAQ inhibitors and application procedures |
WO2016196591A1 (en) * | 2015-06-01 | 2016-12-08 | Indiana University Research & Technology Corporation | Protein tyrosine phosphatases or shp2 inhibitors and uses thereof |
US10654802B2 (en) * | 2016-07-08 | 2020-05-19 | Arizona Board Of Regents On Behalf Of The Unversit | Indoline derivatives and method for using and producing the same |
US20230148589A1 (en) * | 2020-03-31 | 2023-05-18 | Lg Chem, Ltd. | Composition for protecting islet transplantation |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0236251A2 (fr) * | 1986-03-05 | 1987-09-09 | Universite Louis Pasteur (Strasbourg I) | (amino-2 benzyl)-2 tétrahydro-1,2,3,4 isoquinoléines, procédés pour leur obtention et compositions pharmaceutiques les contenant |
US5164295A (en) * | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
WO1994022437A2 (en) * | 1993-03-29 | 1994-10-13 | Queen's University At Kingston | Method for treating amyloidosis |
DE4313118A1 (de) * | 1993-04-22 | 1994-10-27 | Hoechst Ag | Verwendung von 1,2,3,4-Tetrahydroisochinolin-Derivaten als Antimykotika |
WO1996028187A1 (en) * | 1995-03-15 | 1996-09-19 | Queen's University At Kingston | Method for treating amyloidosis |
WO1996037612A1 (en) * | 1995-05-23 | 1996-11-28 | Pfizer Inc. | Transgenic animal models for type ii diabetes mellitus |
WO1997009976A2 (en) * | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3872125A (en) | 1973-03-03 | 1975-03-18 | Sandoz Ag | 3-substituted-4-aryl isoquinolines |
FR2384751A1 (fr) | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
CA1140049A (en) | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
FR2457281A1 (fr) | 1979-05-23 | 1980-12-19 | Meram Lab | Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee |
US4540564A (en) | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
US5087618A (en) | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
FR2529546A1 (fr) | 1982-07-05 | 1984-01-06 | Meram Lab | Nouveaux sels d'amino-(et imino-)acides a, o-sulfoniques n-substitues, vecteurs cationiques de haute penetration cellulaire |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
IT1193590B (it) | 1983-01-07 | 1988-07-08 | Loris Jacopo Bononi | Derivati amino-alchil-solfonici,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
SE454299B (sv) * | 1986-10-08 | 1988-04-18 | Westermark P | Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
DE3940410A1 (de) | 1989-12-04 | 1991-06-06 | Schering Ag | Neue verwendung von nmda-rezeptor-antagonisten |
FR2657164B1 (fr) | 1990-01-16 | 1992-04-03 | Cit Alcatel | Installation de detection de fuite a pompe holweck a prise intermediaire. |
US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5242932A (en) | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
DE4021066A1 (de) | 1990-07-03 | 1992-01-09 | Hoechst Ag | Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden |
DE69232909D1 (de) | 1991-02-22 | 2003-03-06 | Howard K Shapiro | Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe |
IT1245907B (it) * | 1991-05-17 | 1994-10-25 | Alfa Wassermann Spa | Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica. |
US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
EP0611966A1 (en) * | 1993-02-19 | 1994-08-24 | Bayer Corporation | Method, composition and device for measuring the ionic strength or specific gravity of a test sample |
US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
US5643562A (en) | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
AU6836394A (en) | 1993-06-01 | 1994-12-20 | Cortex Pharmaceuticals, Inc. | Use of metabotropic receptor agonists in progressive neurodegenerative deseases |
US5576419A (en) * | 1993-06-30 | 1996-11-19 | Regents Of The University Of Minnesota | Mild solid-phase synthesis of aligned branched triple-helical peptides |
WO1995006477A1 (en) | 1993-08-31 | 1995-03-09 | Gliatech, Inc. | Inhibition of beta amyloid binding to glycosaminoglycans for treatment of alzheimer's disease |
US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
CA2242851A1 (en) | 1995-08-17 | 1997-02-27 | The Ontario Cancer Institute | Protein fibril assembly assay |
JPH0995444A (ja) * | 1995-10-02 | 1997-04-08 | Teijin Ltd | アミロイド蛋白凝集阻害剤 |
US5972956A (en) | 1995-11-02 | 1999-10-26 | Warner-Lambert Company | Inhibition of amyloidosis by 9-acridinones |
AU703540B2 (en) | 1996-03-26 | 1999-03-25 | Meddiss, Incorporated | Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
US6043283A (en) | 1996-09-20 | 2000-03-28 | Baylor College Of Medicine | Tyramine compounds and their neuronal effects |
US5927328A (en) * | 1996-09-26 | 1999-07-27 | Masco Corporation | Self closing faucet with timing mechanism |
KR20000036227A (ko) | 1996-09-27 | 2000-06-26 | 토마스 씨. 서 | 날라다아제조성물, 글루탐산염 이상 치료법 및 동물내의 뉴우런활성법 |
SE9604582D0 (sv) | 1996-12-13 | 1996-12-13 | Astra Ab | Novel compounds |
US5869469A (en) | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
WO1999008685A1 (en) * | 1997-08-18 | 1999-02-25 | Queen's University At Kingston | Phosphono-carboxylate compounds for treating amyloidosis |
CA2301725C (en) * | 1997-08-28 | 2008-11-18 | University Of Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6166320A (en) * | 1998-03-19 | 2000-12-26 | Toyota Jidosha Kabushiki Kaisha | Tandem solar cell |
US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
AU3886200A (en) | 1999-03-15 | 2000-10-16 | Proteotech, Inc. | Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof |
AU4282400A (en) | 1999-04-28 | 2000-11-10 | Neurochem (International) Limited | Compositions and methods for treating amyloidosis |
US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
AU5994900A (en) | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
-
2000
- 2000-05-23 US US09/576,677 patent/US6562836B1/en not_active Expired - Fee Related
- 2000-05-24 JP JP2000619408A patent/JP2003500350A/ja active Pending
- 2000-05-24 NZ NZ541238A patent/NZ541238A/en not_active IP Right Cessation
- 2000-05-24 AU AU49050/00A patent/AU4905000A/en not_active Abandoned
- 2000-05-24 CA CA002684016A patent/CA2684016A1/en not_active Abandoned
- 2000-05-24 NZ NZ566739A patent/NZ566739A/en not_active IP Right Cessation
- 2000-05-24 CN CNB008107203A patent/CN100435785C/zh not_active Expired - Fee Related
- 2000-05-24 AT AT00930923T patent/ATE466571T1/de not_active IP Right Cessation
- 2000-05-24 MX MXPA01011989A patent/MXPA01011989A/es not_active Application Discontinuation
- 2000-05-24 CA CA002373093A patent/CA2373093C/en not_active Expired - Fee Related
- 2000-05-24 NZ NZ552354A patent/NZ552354A/en not_active IP Right Cessation
- 2000-05-24 IL IL14668100A patent/IL146681A0/xx active IP Right Grant
- 2000-05-24 WO PCT/CA2000/000607 patent/WO2000071101A2/en active Application Filing
- 2000-05-24 EP EP00930923A patent/EP1227803B1/en not_active Expired - Lifetime
- 2000-05-24 DE DE60044365T patent/DE60044365D1/de not_active Expired - Lifetime
-
2001
- 2001-11-22 IL IL146681A patent/IL146681A/en not_active IP Right Cessation
-
2003
- 2003-02-05 HK HK03100829.4A patent/HK1050133A1/zh unknown
- 2003-05-02 US US10/429,198 patent/US7393875B2/en not_active Expired - Fee Related
-
2007
- 2007-01-03 IL IL180523A patent/IL180523A0/en unknown
-
2008
- 2008-05-22 US US12/125,842 patent/US7786174B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0236251A2 (fr) * | 1986-03-05 | 1987-09-09 | Universite Louis Pasteur (Strasbourg I) | (amino-2 benzyl)-2 tétrahydro-1,2,3,4 isoquinoléines, procédés pour leur obtention et compositions pharmaceutiques les contenant |
US5164295A (en) * | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
WO1994022437A2 (en) * | 1993-03-29 | 1994-10-13 | Queen's University At Kingston | Method for treating amyloidosis |
DE4313118A1 (de) * | 1993-04-22 | 1994-10-27 | Hoechst Ag | Verwendung von 1,2,3,4-Tetrahydroisochinolin-Derivaten als Antimykotika |
WO1996028187A1 (en) * | 1995-03-15 | 1996-09-19 | Queen's University At Kingston | Method for treating amyloidosis |
WO1996037612A1 (en) * | 1995-05-23 | 1996-11-28 | Pfizer Inc. | Transgenic animal models for type ii diabetes mellitus |
WO1997009976A2 (en) * | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
Also Published As
Publication number | Publication date |
---|---|
US7786174B2 (en) | 2010-08-31 |
IL146681A0 (en) | 2002-07-25 |
IL180523A0 (en) | 2009-02-11 |
NZ566739A (en) | 2009-10-30 |
EP1227803B1 (en) | 2010-05-05 |
US7393875B2 (en) | 2008-07-01 |
JP2003500350A (ja) | 2003-01-07 |
CA2373093C (en) | 2010-01-19 |
CN1377260A (zh) | 2002-10-30 |
ATE466571T1 (de) | 2010-05-15 |
WO2000071101A2 (en) | 2000-11-30 |
NZ541238A (en) | 2007-02-23 |
DE60044365D1 (de) | 2010-06-17 |
US6562836B1 (en) | 2003-05-13 |
MXPA01011989A (es) | 2002-05-06 |
EP1227803A2 (en) | 2002-08-07 |
CA2373093A1 (en) | 2000-11-30 |
AU4905000A (en) | 2000-12-12 |
CA2684016A1 (en) | 2000-11-30 |
US20080227767A1 (en) | 2008-09-18 |
NZ552354A (en) | 2008-04-30 |
IL146681A (en) | 2007-12-03 |
US20040248876A1 (en) | 2004-12-09 |
HK1050133A1 (zh) | 2003-06-13 |
WO2000071101A3 (en) | 2001-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100435785C (zh) | 抑制iapp的化合物或其可药用酯或其可药用盐的制药应用 | |
KR100370522B1 (ko) | 2,4-디술포페닐부틸니트론,그의염및이들의제약스핀트랩으로서의용도 | |
EP1276483B1 (en) | Compositions and methods for treating amyloidosis using sulphonate derivatives | |
EP0937459A2 (en) | Pharmaceutical compositions for the treatment of ischemic brain damage | |
WO2001003680A2 (en) | Compounds for inhibiting diseases and preparing cells for transplantation | |
KR19980081621A (ko) | 과민성 장 증후군의 증상을 치료하기 위한 엔케이-1 수용체 길항물질 | |
WO2006000222A2 (en) | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia | |
US6399658B1 (en) | Composition containing ascorbic acid | |
MXPA02003496A (es) | Derivados de piridinio para el tratamiento de complicaciones vasculares diabeticas y relacionadas con la edad. | |
RU2056416C1 (ru) | Производные тиомочевины, фармацевтическая композиция и способ лечения | |
AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
CN101396352A (zh) | 抑制淀粉样蛋白沉积的方法和化合物 | |
AU2005203635B2 (en) | Methods and compounds for inhibiting amyloid deposits | |
US3852458A (en) | Antidepressive activity of tetramisole | |
JPWO2003013522A1 (ja) | コリン作動性神経障害予防・治療薬 | |
CN101287467A (zh) | 用于调节Lyn激酶活性和治疗相关病症的方法和制剂 | |
NZ626495B2 (en) | Treatment of type i and type ii diabetes | |
JPH02286617A (ja) | 血管新生阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NERVE CHEMICAL ( INTERNATIONAL) LIMITED Free format text: FORMER OWNER: NEWROCHEM INC. Effective date: 20040611 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040611 Address after: Ontario, Canada Applicant after: Univ Kingston Co-applicant after: NEUROCHEM (INTERNATIONAL) Ltd. Address before: Ontario, Canada Applicant before: Univ Kingston Co-applicant before: Newrochem Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: NERVE CHEMICAL ( INTERNATIONAL) LIMITED Free format text: FORMER OWNER: KINGSTON QUEEN S UNIVERSITY; APPLICANT Effective date: 20070309 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070309 Address after: Swiss Val Sewell Applicant after: NEUROCHEM (INTERNATIONAL) Ltd. Address before: Ontario, Canada Applicant before: Univ Kingston Co-applicant before: NEUROCHEM (INTERNATIONAL) Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081126 Termination date: 20110524 |